Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07731789) titled 'Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma' on July 22.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Washington
Condition:
Classic Follicular Lymphoma
Grade 1 Follicular Lymphoma
Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Intervention:
Biological: Rituximab
Biological: Tafasitamab
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure...